MX388660B - DERIVADOS DE N-(SUSTITUIDA-FENIL)-SULFONAMIDA COMO INHIBIDORES DE QUINASA N-(sustituida-fenil)-sulfonamida. - Google Patents
DERIVADOS DE N-(SUSTITUIDA-FENIL)-SULFONAMIDA COMO INHIBIDORES DE QUINASA N-(sustituida-fenil)-sulfonamida.Info
- Publication number
- MX388660B MX388660B MX2018016419A MX2018016419A MX388660B MX 388660 B MX388660 B MX 388660B MX 2018016419 A MX2018016419 A MX 2018016419A MX 2018016419 A MX2018016419 A MX 2018016419A MX 388660 B MX388660 B MX 388660B
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl
- substituted
- sulfonamide
- compounds
- kinase inhibitors
- Prior art date
Links
- -1 N-(SUBSTITUTED-PHENYL)-SULFONAMIDE Chemical class 0.000 title abstract 3
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010089429 PERK kinase Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 230000004906 unfolded protein response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente invención se refiere a compuestos de N-(sustituida-fenil)-sulfonamida, los cuales son extremadamente útiles como inhibidores de las proteínas quinasas (por ejemplo. quinasa PERK) y, en consecuencia, pueden ser empleadas para el tratamiento de desórdenes celulares proliferativos, como el cáncer, o enfermedades asociadas con vías de respuesta a proteinas desplegadas activadas, como la enfermedad de Alzheimer. La presente invención también proporciona métodos para preparar dichos compuestos, composiciones farmacéuticas que los comprenden, así como métodos para el tratamiento de enfermedades, utilizando dichas composiciones farmacéuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16175386 | 2016-06-21 | ||
| PCT/EP2017/064904 WO2017220477A1 (en) | 2016-06-21 | 2017-06-19 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018016419A MX2018016419A (es) | 2019-09-09 |
| MX388660B true MX388660B (es) | 2025-03-20 |
Family
ID=56148248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018016419A MX388660B (es) | 2016-06-21 | 2017-06-19 | DERIVADOS DE N-(SUSTITUIDA-FENIL)-SULFONAMIDA COMO INHIBIDORES DE QUINASA N-(sustituida-fenil)-sulfonamida. |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10561660B2 (es) |
| EP (1) | EP3472165B1 (es) |
| JP (1) | JP6867417B2 (es) |
| KR (1) | KR102500416B1 (es) |
| CN (1) | CN109311894B (es) |
| AU (1) | AU2017279878B9 (es) |
| CA (1) | CA3029097A1 (es) |
| DK (1) | DK3472165T3 (es) |
| ES (1) | ES2964781T3 (es) |
| FI (1) | FI3472165T3 (es) |
| HU (1) | HUE064919T2 (es) |
| IL (1) | IL263739B (es) |
| MX (1) | MX388660B (es) |
| PL (1) | PL3472165T3 (es) |
| PT (1) | PT3472165T (es) |
| RU (1) | RU2753520C2 (es) |
| SI (1) | SI3472165T1 (es) |
| WO (1) | WO2017220477A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017220477A1 (en) | 2016-06-21 | 2017-12-28 | Nerviano Medical Sciences S.R.L. | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors |
| WO2021030238A2 (en) * | 2019-08-09 | 2021-02-18 | Ohm Oncology | Method of synthesis of compound for dual inhibition of jak2 and bet |
| KR20210056827A (ko) * | 2019-11-11 | 2021-05-20 | 일동제약(주) | 신규한 벤젠설폰아미드 유도체 및 그의 용도 |
| MX2022010040A (es) * | 2020-02-17 | 2022-09-05 | Alesta Therapeutics BV | Compuestos moduladores de gcn2. |
| DK4146348T3 (da) | 2020-05-08 | 2024-09-30 | Halia Therapeutics Inc | Inhibitorer af nek7-kinase |
| CN111454261A (zh) * | 2020-05-27 | 2020-07-28 | 南京普锐达医药科技有限公司 | 一种4-氯吡咯并嘧啶化合物的合成方法 |
| JP2023549540A (ja) * | 2020-11-18 | 2023-11-27 | デシフェラ・ファーマシューティカルズ，エルエルシー | Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法 |
| WO2022212326A1 (en) | 2021-03-29 | 2022-10-06 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| PH12023552774A1 (en) | 2021-04-05 | 2024-04-15 | Halia Therapeutics Inc | Nek7 inhibitors |
| WO2023025912A1 (en) | 2021-08-25 | 2023-03-02 | Alesta Therapeutics BV | Use of gcn2 inhibitors in treating cancer |
| JP2024544632A (ja) * | 2021-12-03 | 2024-12-03 | デシフェラ・ファーマシューティカルズ，エルエルシー | Ｇｃｎ２及びｐｅｒｋキナーゼ阻害剤としての複素環式化合物 |
| JP2025512992A (ja) * | 2022-04-08 | 2025-04-22 | アレスタ・セラピューティクス・ベスローテン・フェンノートシャップ | Ｇｃｎ２モジュレーター化合物 |
| EP4491626A4 (en) * | 2022-06-08 | 2025-07-09 | Korea Res Inst Chemical Tech | PHENYLSULFONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER CONTAINING THEM AS ACTIVE INGREDIENT |
| WO2024249493A2 (en) * | 2023-05-30 | 2024-12-05 | Deciphera Pharmaceuticals, Llc | Gcn2 and perk kinase modulators and methods of use thereof |
| WO2025076441A1 (en) * | 2023-10-06 | 2025-04-10 | Alesta Therapeutics BV | Compounds of gcn2 modulators |
| GB202407386D0 (en) | 2024-05-24 | 2024-07-10 | Apollo Ap45 Ltd | 1H-pyrazolo(4,3-D)pyrimidine derivatives |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE242245T1 (de) | 1997-03-19 | 2003-06-15 | Basf Ag | Pyrrolo(2,3-d)pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren |
| JP2002527359A (ja) | 1998-09-18 | 2002-08-27 | ビーエーエスエフ アクチェンゲゼルシャフト | キナーゼインヒビターとしての４−アミノピロリピリミジン |
| GB0625827D0 (en) * | 2006-12-22 | 2007-02-07 | Astex Therapeutics Ltd | New compounds |
| WO2010045542A2 (en) | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| UY33288A (es) | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
| EA027277B1 (ru) * | 2012-10-16 | 2017-07-31 | Альмираль, С.А. | Производные пирроллотриазинона в качестве ингибиторов pi3k |
| EP2989091B1 (en) | 2013-04-04 | 2017-05-10 | Janssen Pharmaceutica NV | Novel n-(2,3-dihydro-1h-pyrrolo[2,3-b]pyridin-5-yl)-4- quinazolinamine and n-(2,3-dihydro-1h-indol-5-yl)-4- quinazolinamine derivatives as perk inhibitors |
| KR20160013028A (ko) * | 2013-05-30 | 2016-02-03 | 플렉시콘, 인코퍼레이티드 | 키나제 조정을 위한 화합물 및 그에 대한 적응증 |
| EP3116877A1 (en) | 2014-03-11 | 2017-01-18 | Glaxosmithkline Intellectual Property (No. 2) Limited | Chemical compounds acting as perk inhibitors |
| WO2017220477A1 (en) * | 2016-06-21 | 2017-12-28 | Nerviano Medical Sciences S.R.L. | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors |
-
2017
- 2017-06-19 WO PCT/EP2017/064904 patent/WO2017220477A1/en not_active Ceased
- 2017-06-19 PL PL17732075.1T patent/PL3472165T3/pl unknown
- 2017-06-19 PT PT177320751T patent/PT3472165T/pt unknown
- 2017-06-19 AU AU2017279878A patent/AU2017279878B9/en active Active
- 2017-06-19 SI SI201731456T patent/SI3472165T1/sl unknown
- 2017-06-19 KR KR1020197001839A patent/KR102500416B1/ko active Active
- 2017-06-19 CN CN201780038709.2A patent/CN109311894B/zh active Active
- 2017-06-19 JP JP2018566910A patent/JP6867417B2/ja active Active
- 2017-06-19 FI FIEP17732075.1T patent/FI3472165T3/fi active
- 2017-06-19 MX MX2018016419A patent/MX388660B/es unknown
- 2017-06-19 ES ES17732075T patent/ES2964781T3/es active Active
- 2017-06-19 HU HUE17732075A patent/HUE064919T2/hu unknown
- 2017-06-19 EP EP17732075.1A patent/EP3472165B1/en active Active
- 2017-06-19 US US16/312,061 patent/US10561660B2/en active Active
- 2017-06-19 CA CA3029097A patent/CA3029097A1/en active Pending
- 2017-06-19 RU RU2019101002A patent/RU2753520C2/ru active
- 2017-06-19 DK DK17732075.1T patent/DK3472165T3/da active
-
2018
- 2018-12-16 IL IL263739A patent/IL263739B/en unknown
-
2019
- 2019-12-19 US US16/721,267 patent/US10918642B2/en active Active
-
2021
- 2021-01-04 US US17/140,471 patent/US11491158B2/en active Active
-
2022
- 2022-09-29 US US17/936,576 patent/US11833153B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX388660B (es) | DERIVADOS DE N-(SUSTITUIDA-FENIL)-SULFONAMIDA COMO INHIBIDORES DE QUINASA N-(sustituida-fenil)-sulfonamida. | |
| EA201792047A1 (ru) | Новые соединения | |
| MX387394B (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| MX382607B (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa. | |
| BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
| MX2020007898A (es) | Moduladores de cinasa de proteina asociada con rho. | |
| EA201990019A1 (ru) | Соединения и композиции для подавления активности shp2 | |
| BR112018071585A2 (pt) | formulações de um inibidor de lsd1 | |
| MX387097B (es) | Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas. | |
| EA201890001A1 (ru) | Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk) | |
| EA201491592A1 (ru) | Соединения индолов и индазолов, активирующие ampk | |
| MX383213B (es) | Inhibidores de tirosina-cinasas | |
| EA201792619A1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы | |
| EA201790492A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| MX367918B (es) | Compuestos heterociclicos fusionados como inhibidores de proteina quinasa. | |
| BR112016006978A2 (pt) | inibidores de tirosina quinase de bruton | |
| EA201391682A1 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
| EA201790995A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
| EA201792304A1 (ru) | Комбинированная терапия для лечения рака | |
| EA201891399A1 (ru) | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| EA202090414A1 (ru) | Соединения и их применение | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| BR112019006887A2 (pt) | ativadores do fluxo autofágico e fosfolipase d e depuração de agregado proteico, incluindo tau e tratamento de proteinopatias |